These findings also highlight the importance of FOXO3 and FOXM1 as biomarkers for prediction of drug resistance or sensitivity respectively when targeting the PI3K-AKT pathway in ER+ BC (Fig. 6E). The gene discussed is AKT1; the disease is breast cancer.